https://www.selleckchem.com/
•There is a concern that renin-angiotensin-aldosterone system (RAAS) blockers increase susceptibility to coronavirus 2019 (COVID-19).•There no evidence that treatment with RAAS blockers worsens the course of COVID-19.•Discontinuation of RAAS blockers may exacerbate cardiovascular comorbidities.•RAAS blockers should be continued in patients with otherwise stable conditions.COVID-19 has officially consumed every nurse leader's time and efforts. The purpose of this article is to share early learnings from the West Coast of the United States, where the first US
Like
Comment
Share
